Suppr超能文献

坎地沙坦与普萘洛尔联合治疗对比普萘洛尔单药治疗对降低门静脉高压的效果。

Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension.

作者信息

Kim Jae Hyun, Kim Jung Min, Cho Youn Zoo, Na Ji Hoon, Kim Hyun Sik, Kim Hyoun A, Kang Hye Won, Baik Soon Koo, Kwon Sang Ok, Cha Seung Hwan, Kim Young Ju, Kim Moon Young

机构信息

Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.

Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea. ; Department of Cell Therapy and Tissue Engineering, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Korea.

出版信息

Clin Mol Hepatol. 2014 Dec;20(4):376-83. doi: 10.3350/cmh.2014.20.4.376. Epub 2014 Dec 24.

Abstract

BACKGROUND/AIMS: Angiotensin receptor blockers (ARBs) inhibit activated hepatic stellate cell contraction and are thought to reduce the dynamic portion of intrahepatic resistance. This study compared the effects of combined treatment using the ARB candesartan and propranolol versus propranolol monotherapy on portal pressure in patients with cirrhosis in a prospective, randomized controlled trial.

METHODS

Between January 2008 and July 2009, 53 cirrhotic patients with clinically significant portal hypertension were randomized to receive either candesartan and propranolol combination therapy (26 patients) or propranolol monotherapy (27 patients). Before and 3 months after the administration of the planned medication, the hepatic venous pressure gradient (HVPG) was assessed in both groups. The dose of propranolol was subsequently increased from 20 mg bid until the target heart rate was reached, and the candesartan dose was fixed at 8 mg qd. The primary endpoint was the HVPG response rate; patients with an HVPG reduction of >20% of the baseline value or to <12 mmHg were defined as responders.

RESULTS

The mean portal pressure declined significantly in both groups, from 16 mmHg (range, 12-28 mmHg) to 13.5 mmHg (range, 6-20 mmHg) in the combination group (P<0.05), and from 17 mmHg (range, 12-27 mmHg) to 14 mmHg (range, 7-25 mmHg) in the propranolol monotherapy group (P<0.05). However, the medication-induced pressure reduction did not differ significantly between the two groups [3.5 mmHg (range, -3-11 mmHg) vs. 3 mmHg (range, -8-10 mmHg), P = 0.674]. The response rate (55.6% vs. 61.5%, P = 0.435) and the reductions in mean blood pressure or heart rate also did not differ significantly between the combination and monotherapy groups.

CONCLUSIONS

The addition of candesartan (an ARB) to propranolol confers no benefit relative to classical propranolol monotherapy for the treatment of portal hypertension, and is thus not recommended.

摘要

背景/目的:血管紧张素受体阻滞剂(ARBs)可抑制活化的肝星状细胞收缩,并被认为可降低肝内阻力的动态部分。本前瞻性随机对照试验比较了ARB坎地沙坦与普萘洛尔联合治疗与普萘洛尔单药治疗对肝硬化患者门静脉压力的影响。

方法

2008年1月至2009年7月期间,53例具有临床显著性门静脉高压的肝硬化患者被随机分为接受坎地沙坦与普萘洛尔联合治疗组(26例患者)或普萘洛尔单药治疗组(27例患者)。在给予计划用药前及用药3个月后,对两组患者的肝静脉压力梯度(HVPG)进行评估。随后普萘洛尔剂量从20mg每日两次开始增加,直至达到目标心率,坎地沙坦剂量固定为8mg每日一次。主要终点为HVPG反应率;HVPG降低>基线值的20%或降至<12mmHg的患者被定义为反应者。

结果

两组患者的平均门静脉压力均显著下降,联合治疗组从16mmHg(范围12 - 28mmHg)降至13.5mmHg(范围6 - 20mmHg)(P<0.05),普萘洛尔单药治疗组从17mmHg(范围12 - 27mmHg)降至14mmHg(范围7 - 25mmHg)(P<0.05)。然而,两组间药物诱导的压力降低无显著差异[3.5mmHg(范围 - 3 - 11mmHg)对3mmHg(范围 - 8 - 10mmHg),P = 0.674]。联合治疗组与单药治疗组的反应率(55.6%对61.5%,P = 0.435)以及平均血压或心率的降低也无显著差异。

结论

在普萘洛尔基础上加用坎地沙坦(一种ARB)相对于经典的普萘洛尔单药治疗在治疗门静脉高压方面并无益处,因此不推荐使用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dd3/4278069/821ab961de20/cmh-20-376-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验